Airplasma

Airplasma is an innovative technology that generates plasma energy by ionizing the surrounding air using high-frequency and high-voltage electromagnetic energy, eliminating the need for external inert gases like Argon or Helium. This breakthrough technology transforms air into a highly efficient conductor of energy, offering potential applications in diverse fields such as medicine, manufacturing, and more.

The Airplasma® technology consists in the elimination of the isolating power of the air through an electronic process that makes it an ideal electric conductor. This technology allows applications at low temperature. Operating at a maximum temperature of 122°F (50° C) it is possible to induce tissue vaporization for ablation, tissue dissection or cutting and small vessels hemostasis. In traditional electrosurgery, cutting and coagulation procedures are produced at temperatures over 244°F (100° C) and voltage spikes over 5,000 V.

Onemystis uses the new Airplasma technology, which works by gas - in the case, air-ionisation. Air is passed through a strong electromagnetic field generated safely sing a high voltage/low current energy source. This releases energy (plasma) which can vaporise tissue at low temperature.

• Reduced Thermal Damage: By operating at lower temperatures and without temperature peaks, Airplasma may help minimize thermal damage to surrounding tissues during surgical procedures. This can lead to faster healing and reduced post-operative complications.

• Faster Procedures: The ability to create plasma energy from the air without the need for complex setup involving external gases can streamline surgical procedures, reducing the time patients spend under anesthesia and on the operating table.

• Precise Dissection: Airplasma's ability to provide precise dissection and instantaneous hemostasis on small vessels can contribute to more accurate and less invasive surgeries, potentially leading to better outcomes and shorter recovery times.

• Safety: The elimination of external gases and the reduction of electrical interference with patient monitoring devices can enhance patient safety during surgeries, minimizing the risk of complications or discomfort.

• Minimized Scarring: By preserving surrounding tissues and reducing heat production, Airplasma may help minimize scarring, improving the cosmetic results of surgical procedures.

• Return on Investment (ROI): While Onemytis® 2 may have an initial one-time cost or periodic maintenance expenses, the benefits it offers can justify this investment. Clinics can leverage the state-of-the-art nature of this device to charge a premium for surgeries. Patients are often willing to pay more for procedures that promise reduced risks, shorter recovery times, and improved outcomes. This means that clinics can potentially recoup their investment more quickly through higher procedure fees and increased patient volume.

• Decreased Drug Costs: One of the significant cost-saving aspects of Onemytis® 2 is the reduced need for anesthetics and sedatives. These drugs can be expensive, and their use often contributes to the overall cost of surgery. With the device's ability to minimize the need for these medications, clinics not only reduce direct drug costs but also lower the risk of drug-related complications or side effects. This leads to smoother post-operative recoveries, which can increase patient satisfaction and trust in the clinic's services. Satisfied patients are more likely to return for future procedures and recommend the clinic to others, potentially boosting repeat business and referrals.

• Opening New Revenue Streams: Onemytis® 2 caters to a specific market segment: patients who may not be suitable candidates for conventional electrosurgery due to safety concerns. By offering a safer alternative, veterinary practices can tap into this previously underserved market. This expanded clientele can result in increased revenue streams for the clinic, as they attract patients who may have otherwise hesitated to undergo surgery. This broader patient base can lead to a more stable and prosperous practice.

• Cost Comparison: To evaluate the financial impact of adopting Onemytis® 2, clinics can conduct a thorough cost analysis. This analysis should compare the average costs associated with current surgical techniques, including equipment, disposables, drug expenses, and potential complications, with the total cost of adopting and maintaining the new equipment. Consideration should also be given to potential revenue increases due to premium pricing and expanded patient volumes.

​​

While there may be initial costs associated with acquiring and maintaining Onemytis® 2, the device offers various financial advantages to clinics. These benefits include the ability to charge higher fees for state-of-the-art procedures, reduced drug costs, increased client trust and loyalty, and the opportunity to tap into new patient segments.

When used correctly and in accordance with established guidelines, it has the potential to offer benefits in terms of reduced thermal damage, faster procedures, and improved precision in surgical applications. However, its safety should be evaluated in specific medical contexts and patient populations.​​